Indicazioni terapeutiche approvate e ulteriori possibili applicazioni dei farmaci biologici anti-TNFα

Translated title of the contribution: Approved indications and other possible utilizations of anti-TNFα biologic drugs

Walter Grassi, C. Montecucco

Research output: Contribution to journalArticlepeer-review

Abstract

The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Translated title of the contributionApproved indications and other possible utilizations of anti-TNFα biologic drugs
Original languageItalian
Pages (from-to)30-33
Number of pages4
JournalReumatismo
Volume57
Issue numberSUPPL. 4
Publication statusPublished - 2005

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Approved indications and other possible utilizations of anti-TNFα biologic drugs'. Together they form a unique fingerprint.

Cite this